Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models

Author(s):

Sanaa K. Bardaweel*, Lina A. Dahabiyeh, Bushra M. Akileh, Dana D. Shalabi, Afnan K. AlHiary, Judy Pawling, James W. Dennis and Anas M. Abdel Rahman   Pages 1611 - 1621 ( 11 )

Abstract:

<P>Background: Chronic inflammation plays a crucial role in the initiation, promotion, and invasion of tumors, and thus the antiproliferative effects of numerous anti-inflammatory drugs have been frequently reported in the literature. Upregulation of the pro-inflammatory enzyme cyclooxygenase-2 (COX-2) has been linked to various human cancers, including breast cancer. <P> Objectives: This research aims to investigate the antiproliferative activity of different Non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective and non-selective agents, against various breast cancer cell lines and to elucidate possible molecular pathways involved in their activity. <P> Methods: The antiproliferative and combined effects of NSAIDs with raloxifene were evaluated by MTT assay. Cell migration was assessed using a wound-healing assay. The mechanism of cell death was determined using the Annexin V-FITC/ propidium iodide staining flow cytometry method. A mass spectrometry-based targeted metabolomics approach was used to profile the metabolomic changes induced in the T47d cells upon drug treatment. <P> Results: Our results have demonstrated that celecoxib, a potent and selective COX-2 inhibitor, resulted in significant antiproliferative activity against all examined breast cancer cell lines with IC50 values of 95.44, 49.50. and 97.70 μM against MDA-MB-231, T47d, and MCF-7, respectively. Additionally, celecoxib exhibited a synergistic effect against T47d cells combined with raloxifene, a selective estrogen receptor modulator. Interestingly, celecoxib treatment increased cell apoptosis and resulted in substantial inhibition of cancer cell migration. In addition, the metabolomic analysis suggests that celecoxib may have affected metabolites (n = 43) that are involved in several pathways, including the tricarboxylic acid cycle, amino acids metabolism pathways, and energy production pathways in cancer cells. <P> Conclusion: Celecoxib may possess potential therapeutic utility for breast cancer treatment as monotherapy or in combination therapy. The reported metabolic changes taking place upon celecoxib treatment may shed light on possible molecular targets mediating the antiproliferative activity of celecoxib in an independent manner of its COX-2 inhibition.</P>

Keywords:

Breast cancer, NSAIDs, celecoxib, metabolomics, combination therapy, raloxifene.

Affiliation:

Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue R988, Toronto, Ontario M5G 1X5, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue R988, Toronto, Ontario M5G 1X5, Metabolomics Section, Department of Clinical Genomics, Center for Genomics Medicine, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, 11564

Graphical Abstract:

Read Full-Text article